Hope springs for April inhibition
Novartis’s Chinook takeout gives a boost to others pursuing this long-researched target, including Vera and Alpine.
Spotlight − late-stage challengers in Parkinson’s disease
Biogen and Denali stand out among small developers targeting Parkinson's.
Spotlight – Few signs of gout pipeline flaring up
Asian developers dominate biopharma’s gout pipeline, with Selecta and Sobi’s SEL-212 standing out as a rare globally focused project.
Gene editing: overhyped or unstoppable tide?
A new report from Evaluate Vantage looks at recent developments in gene editing and delivery.
Spotlight – Travere trips up but others are following in rare kidney disease
Chinook, Vertex and Dimerix are following Travere in FSGS, but several dropouts point to challenges in this disease.
Spotlight – J&J takes on Medtronic and Boston in pulsed field ablation
The group is fast developing its new atrial fibrillation devices. But will it be fast enough?
Spotlight – following Humira in hidradenitis suppurativa
Immune agents old and new are trying to make a splash in what could turn into a billion-dollar market.
Spotlight – Vertex flexes its dealmaking muscle
The developer has two new collaborations in rare dystrophies, with Entrada and Tevard, but work is early and certain rivals are some way ahead.
Spotlight – Seeking target selectivity in achondroplasia
As Bridgebio appears to validate FGFR3 as a target in achondroplasia, who else might follow suit?